tbuckley/cabot-search huggingface dataset:
Psychiatric complications in a patient with complex partial seizures [clinical conference]
Authors: H P Blumberg, G S Kanwal, N Relkin, S Mattis, M Viederman, G J Makari
Journal: American Journal of Psychiatry (1996)

This case highlights the complexities of evaluating and treating psychiatric symptoms that are concurrent with a seizure disorder. Interictal and postictal psychoses, affective disorders, personality changes, and cognitive deficits are common problems that require modified psychiatric treatments.
The t(6;8)(q27;p11) Translocation in a Stem Cell Myeloproliferative Disorder Fuses a Novel Gene, FOP, to Fibroblast Growth Factor Receptor 1
Authors: Cornel Popovici, Bin Zhang, Marie-José Grégoire, Philippe Jonveaux, Marina Lafage-Pochitaloff, Daniel Birnbaum, Marie-Josèphe Pébusque
Journal: Blood (1999)
Abstract 5590: Reliability of medical records in diagnosing inflammatory breast cancer in Egypt
Authors: Lynne Le, Catherine Schairer, Ahmed Hablas, Mohamed Ramadan, Sofia Merajver, Ibrahim Seifeldein, Amr Soliman
Journal: Cancer Research (2015)

Abstract Inflammatory breast cancer (IBC) is a rare and aggressive form of breast cancer characterized by diffuse erythema and edema (peau d’orange) of the skin of the breast. It does not include neglected locally advanced cancer of the breast presenting late in the course of the disease. IBC is primarily a clinical diagnosis, but also requires pathologic confirmation of breast cancer. The purpose of this study was to examine the reliability of medical records for diagnosing IBC in patients at two centers in Tanta, Egypt (Gharbiah Cancer Society and Tanta Cancer Center) which participated in an epidemiologic case-case study of IBC and non-IBC in 2009-2010. IBC patients were recruited to the case-case study at diagnosis based on clinical examination; detailed information on the extent and duration of signs used for the diagnosis of IBC was recorded. Information on signs of IBC similar to those collected in the case-case study was abstracted from the medical records of the hospitals where case-case study patients were recruited during the same time period, then linked and compared to the signs observed from clinical examination for the case-case study. A total of 40 IBC cases were recruited into the case-case study during 2009-2010. Medical record information was available for 31 of these cases. Twenty-eight of these 31 cases were reported to have erythema and 28 edema/peau d’orange based on the clinical examination for the case-case study. Of those with erythema, 16 (57.1%) also had erythema/inflammation listed in the medical record; of those with edema/peau d’orange, 23 (82.1%) had this mentioned in the medical record. Erythema was noted on the medical record but not recorded in the case-case study for 2 cases; there were no cases in which edema/peau d’orange was present in the medical record and not in the case-case study. Our analysis indicates that medical records at these cancer centers often have missing information regarding the presence of signs that are necessary to the diagnosis of IBC. Overall, this study suggests that medical record review is not sufficient to identify IBC cases for an epidemiologic study. Citation Format: Lynne Le, Catherine Schairer, Ahmed Hablas, Mohamed Ramadan, Sofia Merajver, Ibrahim Seifeldein, Amr Soliman. Reliability of medical records in diagnosing inflammatory breast cancer in Egypt. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 5590. doi:10.1158/1538-7445.AM2015-5590
Abstract 16063: Impact of Mechanical Factor and Biologic Response on Severe In-Stent Lumen Narrowing in Currently Approved Drug-Eluting Stents
Authors: Kenji Sakata, Katsuhisa Waseda, Hiromasa Otake, Daisaku Nakatani, Teruyoshi Kume, Paul G Yock, Peter J Fitzgerald, Yasuhiro Honda
Journal: Circulation (2010)
Mdr1 gene expression as a marker of treatment response in non-small cell lung cancer (NSCLC).
Authors: R. Luque, C. Melguizo, E. Gonzalez, J. C. Prados, J. Martínez, A. Rama, J. Valdivia, R. Ortiz, V. Conde, J. R. Delgado
Journal: Journal of Clinical Oncology (2010)

e13151 Background: NSCLC is frequently chemoresistant. Multidrug resistance phenotype is involved in the development of chemoresistance. It has been related to several proteins expression, like P-glycoprotein (mdr1 gene). We examined whether elevated mdr1 expression levels in peripheral blood mononuclear cells (PBMC) predict treatment response. Methods: We studied mdr1 gene expression in PBMC of 23 patients with NSCLC, advanced stages in most of the cases, who had not received treatment previously. Blood extraction of 5ml was made to each patient before (hour 0) and after paclitaxel-carboplatin chemotherapy (hour 6). The mdr1 gene expression levels were assessed by quantitative reverse transcription polymerase chain reaction. Results: After treatment, we found mdr1 overexpression in 22 patients. Expression levels were randomly distributed, so that overexpression under 3 was considered low level of expression, and overexpression above 4 was considered high level of expression. High levels were found in 11 patients, and low levels were observed in the other 11 patients. The relationship between mdr1 expression and the treatment response was found to be not significant (p 0,68). No correlation was found between mdr1 expression and survival rate (p 0,54). No significant differences in expression were found in the other variables: gender, tobacco habit, weight loss at the diagnosis, tumor staging, and tumor histology. Conclusions: Our results suggest that the combined treatment with paclitaxel-carboplatin induces mdr1 overexpression in PBMN of patients with NSCLC, but mdr1 expression is not a predictive factor for treatment response nor a prognostic factor of the disease. No significant financial relationships to disclose.
Molecular profiling of patients (pts) with colorectal cancer (CRC) and matched targeted therapy (MTA) in phase I clinical trials.
Authors: Rodrigo Dienstmann, Gessami Sanchez-Olle, Danila Serpico, Jordi Rodon Ahnert, Cristina Saura, Teresa Macarulla, Maria Elena Elez Fernandez, Maria Alsina, Jose Manuel Perez-Garcia, Jaume Capdevila, Guillem Argiles, Irene Brana, Cristina Cruz, Analia Azaro, Debora Moreno-Fernandez, Claudia Aura, Javier Hernandez-Losa, Ana Vivancos, Santiago Ramon y Cajal, Josep Tabernero
Journal: Journal of Clinical Oncology (2012)

3014 Background: Molecular prescreening and biomarker enrichment strategies in Phase 1 trials with targeted therapies are anticipated to improve the outcomes of affected pts. Methods: As part of our personalized oncology program, tumors from pts with advanced chemorefractory CRC were analyzed for specific molecular aberrations (KRAS/ BRAF/ PIK3CA mutations [mut], PTEN and pMET expression) at the Vall d'Hebron Molecular Pathology and Genomics Labs. Those whose tumors were found to have a dysregulation were offered a Phase 1 trial with MTA. Results: During 2010 and 2011, tumor molecular analysis was performed in 254 pts: KRAS mut (80/254, 31.5%), BRAF mut (24/196, 12.2%), PIK3CA mut (15/114, 13.2%), KRAS+PIK3CA mut (9/114, 7.9%), PTEN low (97/183, 53.0% - HSCORE&lt;50; 45/183, 24.6% - PTEN null), KRAS mut + PTEN low (38/138, 20.8%), pMET high (38/64, 59.4% with HSCORE&gt;30). In total, 68 pts (median, age 63 yrs; prior therapies 3), received 82 different matched therapies. Type of MTA: PI3K pathway inh (if PIK3CA mut, n=10; or PTEN low, n=32), MEK+PI3K pathway inh (if KRAS mut, n=10; or BRAF mut, n=1), second-generation anti-EGFR mAbs (if KRAS wild-type, n=11), anti-HGF mAb (if pMET high, n=10), mTOR inh + anti-IGFR-1R mAb (if PTEN low, n=5) and BRAF inh (if BRAF mut, n=3). Median time to treatment failure (TTF) with MTA was 7.9 weeks (CI95%:7.6-8.1) vs. 16.3 weeks (CI95%:13.9-18.7) for their prior systemic antitumor therapy (p&lt;0.001). If prior therapy non-standard (according to NCCN guidelines, n=39), TTF with MTA 7.9 weeks (CI95%:6.8-8.9) vs. TTF with prior therapy 8.7 weeks (CI95%:7.3-10.1). If an approved standard regimen (n=43), TTF with MTA 7.9 weeks (CI95%:7.6-8.1) vs. TTF with prior therapy 21.9 weeks (CI95%:15.0-28.7). Partial response was seen in one pt (1.2%, PI3K inh with PIK3CA mut) and stable disease &gt; 16 weeks in 10 cases (12.2%). Clinical benefit, defined as a TTF ratio ≥ 1.3 (TTF on MTA/ TTF on prior therapy), was seen with 15.9% of the therapies (13/82). Conclusions: Preliminary results suggest that matching chemorefractory CRC patients with targeted agents in early clinical trials based on the current molecular profile does not result in longer TTF compared to their prior therapy.
High-Sensitivity Hematopoietic Chimerism By qPCR For Relapse Prediction and Specific Identification Of HLA Loss Leukemic Variants
Authors: Luca Vago, Benedetta Mazzi, Lorenza Chiesa, Raffaella Greco, Cinzia Pultrone, Eleonora Toffoletti, Cristina Toffalori, Pietro Crivello, Veronica Tettamanzi, Lara Crucitti, Maria Teresa Lupo Stanghellini, Andrea Assanelli, Consuelo Corti, Massimo Bernardi, Jacopo Peccatori, Chiara Bonini, Douglas A. Bost, Fabio Ciceri, Katharina Fleischhauer
Journal: Blood (2013)
Abstract 4691: Endomyocardial Dysfunction in Patients with Severe Aortic Regurgitation and Preserved Ejection Fraction: A Speckle Tracking Echocardiographic Study
Authors: Yoshihiro Seo, Tomoko Ishizu, Noriko Iida, Tomoko Machino, Ryou Kawamura, Shigeyuki Watanabe, Kazutaka Aonuma
Journal: Circulation (2008)

Potential myocardial dysfunction may be present in patients with significant aortic regurgitation (AR) and preserved left ventricular ejection fraction (LVEF). Newly developed software for speckle tracking imaging (STI) allows separate analysis of endo- and epimyocardial strain. The aim of this study was to assess the relationship between endo- and epimyocardial radial strain (RS) distribution and AR severity in identifying the potential myocardial dysfunction in patients with significant AR and LVEF&gt;50%, and its correlation with postoperative LV function. We studied 47 patients with AR and 26 control subjects. Degree of AR was classified according to standard echocardiographic criteria as moderate in 16 and severe in 23 patients. STI was analyzed with the new software (Toshiba Medical Systems, Tokyo, Japan). For STI analysis, an endocardial and epicardial border line were each manually traced at end-systole on a short-axis B-mode image at the mid-ventricular level; peak RS of total, endomyocardium, and epicardium were automatically calculated. Endomyocardial RS was reduced in patients with severe AR compared to control subjects and patients with moderate AR (Figure ). Postoperative changes in LVEF were well correlated with the ratio of baseline endomyocardial RS to epimyocardial RS (n=21, r=−0.69, p&lt;0.001). Endomyocardial RS was reduced in patients with severe AR. Assessment of STI-derived RS distribution may be useful to identify potential myocardial dysfunction and postoperative LV functional deterioration in patients with severe AR and preserved EF.
Bicyclist Deaths Associated with Motor Vehicle Traffic — United States, 1975–2012
Authors: Jason Vargo, Benjamin G. Gerhardstein, Geoffrey P. Whitfield, Arthur Wendel
Journal: MMWR Morbidity and Mortality Weekly Report (2015)

Physical activity, including bicycling, is linked with multiple health benefits. However, although bicycles account for only about 1% of trips across all modes of transportation, on a per trip basis, bicyclists die on U.S. roads at a rate double that of vehicle occupants. In 2009, an estimated 392 billion trips (across all modes) were taken in the United States, including 4.1 billion bicycle trips, and 33,808 deaths occurred on U.S roadways (across all modes), including 630 bicyclist deaths. This report examines mortality trends among cyclists using national collision data from the Fatality Analysis Reporting System (FARS) for the period 1975-2012. Annual rates for cyclist mortality decreased 44%, from 0.41 to 0.23 deaths per 100,000 during this period, with the steepest decline among children aged <15 years. In recent years, reductions in cyclist deaths have slowed. However, age-specific cyclist mortality rates for adults aged 35-74 years have increased since 1975. Multifaceted approaches to bicyclist safety have been shown to be effective in increasing bicycling while decreasing traffic injuries and fatalities. With U.S. adults choosing to walk and cycle more, implementation of these approaches might help counter recent increases in adult cyclist deaths.
Abstract 4180: Assessment of Hibernating Myocardium by Contrast Enhanced Computed Tomography in a Porcine Model
Authors: Gardar Sigurdsson, Edward O McFalls, Jesus A Cabrera, Melanie Crampton, Herbert B Ward, Rosemary F Kelly
Journal: Circulation (2008)

Contrast enhanced computed tomography (CT) is able to assess coronary stenosis and left ventricular function. Due to first pass effect it is able to assess surrogate markers of myocardial perfusion. We assessed the hypothesis that computed tomography can detect hibernating myocardium. Methods and results: A well-established porcine model of hibernating myocardium was used for this study. In this model of chronic coronary stenosis there is ~20% reduction in regional myocardial perfusion. Six pigs underwent instrumentation of the proximal left anterior descending (LAD) coronary artery with an external constrictor. Paired Student-T test was used to compare LAD territory and opposite myocardial segments. After 12 weeks echocardiographic studies detected regional left ventricular dysfunction by M-mode to the LAD territory (Table ). At that time EKG guided computed tomography showed severe stenosis to the LAD. Myocardial signal density (MSD) by CT was assessed in 24 opposing segments during diastole (Hounsfield Units). MSD within the territory of the LAD was significantly lower than MSD of opposing segments (Table ). Ratio of signal density (RSD) between myocardium and left ventricular cavity was significantly lower within the LAD territory in comparison to opposing segments (Table ). Conclusion: In a well-established porcine model of hibernating myocardium contrast enhanced computed tomography was able to detect areas of decreased attenuation suggesting that CT might be able to detect hibernating myocardium. Table
We need to look critically at evidence for universal use
Authors: Martyn J Parker
Journal: BMJ (2008)

The article by Phillips et al is yet another so called evidence based report that fails to appreciate the clinical aspect of thromboembolism.1 The report mentions only the incidence of the surrogate outcome measure of asymptomatic venous thromboembolism. Clinical outcomes of clinical deep vein thrombosis, pulmonary embolism, and …
Abstract 1535: Omentin: A novel adipokine linking visceral obesity to ovarian cancer progression
Authors: Chi Lam Au Yeung, Ngai Na Co, Michaela Onstad, Tsz-Lun Yeung, Cecilia S. Leung, Rosemarie Schmandt, Karen H. Lu, Samuel C. Mok
Journal: Cancer Research (2015)

Abstract Advanced stage serous ovarian cancer metastasizes preferentially to the omentum, which is a major site of intra-abdominal fat accumulation, suggesting that the omental microenvironment is a favorable niche for ovarian cancer cells. The 5-year survival drops to below 50% for the cancer cases that spread beyond the pelvis to the omentum. It has also become apparent that obesity contributes to a poor clinical outcome. The mechanisms by which omental adipose tissue promotes tumor growth and disease progression are not entirely clear. Using transcriptome profiling analysis on the microdissected adipose tissue from patients with benign gynecologic diseases and from patients with advanced high-grade serous ovarian cancer (HGSOC), we found that a novel adipokine called omentin (Intestinal Lactoferrin Receptor ITLN1) was significantly down-regulated in ovarian cancer associated adipose tissue compared with the normal adipose tissue. Survival correlation studies demonstrated that patients with serum ITLN1 levels of &amp;gt;350 ng/mL at the time of first treatment experienced longer survival times than those with lower levels of ITLN1. We showed that ITLN1 suppressed the ovarian cancer cell migration ability and invasion potential in vitro. To delineate the underlying molecular mechanisms, RNA sequencing and pathway analyses were performed on ITLN1 treated ovarian cancer cells and we identified MMP1 as one of the potential mediators. It has been shown that MMP1 expression was induced by lactoferrin, which is abundant in ascites. We hypothesized ITLN1 could abrogate the effect of lactoferrin on ovarian cancer motility and invasion potential. Our preliminary data suggested that secreted ITLN1 may sequester lactoferrin in the ascites, thereby preventing it from binding to the low-density-lipoprotein-receptor-related-protein-1 (LRP-1) on ovarian cancer cell surface and thus inactivate downstream signaling pathways that control MMP1 expression. The study provides the first evidence that ovarian cancer cells modify the visceral adipose tissue through down-regulation of omentin to facilitate their growth in the omental microenvironment. Citation Format: Chi Lam Au Yeung, Ngai Na Co, Michaela Onstad, Tsz-Lun Yeung, Cecilia S. Leung, Rosemarie Schmandt, Karen H. Lu, Samuel C. Mok. Omentin: A novel adipokine linking visceral obesity to ovarian cancer progression. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 1535. doi:10.1158/1538-7445.AM2015-1535
Transfection with Protein Kinase Cα Confers Increased Multidrug Resistance to MCF-7 Cells Expressing P-Glycoprotein
Authors: Gang Yu, Shakeel Ahmad, Angelo Aquino, Craig R. Fairchild, Jane B. Trepel, Shigeo Ohno, Koichi Suzuki, Takashi Tsuruo, Kenneth H. Cowan, Robert I. Glazer
Journal: Cancer Communications (1991)

Cross-resistance to anticancer drugs, termed multidrug resistance (mdr), has been functionally associated with the expression of a plasma membrane energy-dependent efflux pump, termed P-glycoprotein, the product of the mdr1 gene. When MCF-7 breast carcinoma cells were transfected with the human mdr1 gene (BC-19 cells), they expressed levels of P-glycoprotein equivalent to those of cells selected for resistance to doxorubicin (MCF-7/ADR) but exhibited 10- to 50-fold less resistance to doxorubicin and vinblastine. We have now demonstrated that when BC-19 cells were stably transfected with protein kinase C alpha (PKC alpha), resistance to doxorubicin and vinblastine was increased; wild-type MCF-7 cells transfected with PKC alpha did not exhibit any change in drug resistance. Increased resistance in PKC alpha-transfected BC-19 cells was associated with enhanced PKC activity and phosphorylation of P-glycoprotein and decreased drug accumulation. The PKC activator, phorbol dibutyrate, further increased resistance to doxorubicin and stimulated P-glycoprotein phosphorylation. These results demonstrate that transfection of P-glycoprotein-expressing cells with PKC resulted in increased mdr and that PKC may have served as an important modulator of this process.
Activity of ofatumumab (OFA), a fully human monoclonal antibody targeting CD20, against rituximab (RTX)-sensitive (RSCL) and rituximab-resistant cell lines (RRCL), in vivo, and primary tumor cells derived from patients with B-cell lymphoma.
Authors: M. J. Barth, F. J. Hernandez-Ilizaliturri, C. Mavis, P. Tsai, J. F. Gibbs, M. S. Czuczman
Journal: Journal of Clinical Oncology (2010)

8095 Background: RTX has changed the treatment paradigm for B-cell neoplasms and is associated with improved outcomes, but also appears to be changing the sensitivity of relapsed lymphoma. OFA is a new mAb that targets a novel membrane-proximal epitope on CD20. OFA has received marketing approval in the US for fludarabine and alemtuzumab refractory CLL, and is currently evaluated in several clinical trials. To better define OFA's activity, we conducted pre-clinical studies in a panel of RSCL, RRCL, primary lymphoma cells (n=17), and in vivo. Methods: RRCL were generated by repeated exposure (i.e. 10 passages) of sensitive cells to escalating doses of RTX ± human serum. Antibody- dependant cellular cytotoxicity (ADCC) and complement-mediated cytotoxicity (CMC) assays were performed to demonstrate changes in sensitivity to RTX. Lymphoma cells were labeled with 51Cr prior to incubation with RTX or OFA (1 or 10 mg/ml) plus human serum. 51Cr-release was measured and the percentage of lysis was calculated. Surface CD20 levels were determined by flow cytometry. SCID mice were inoculated via tail vein with Raji cells (day 0) and assigned to observation versus 4 doses of either OFA or RTX (1 or 10mg/kg/dose). Results: OFA was more potent than RTX in elucidating effective CMC at the doses tested not only in RSCL, but also in all RRCL (all passages) tested. OFA was more active than RTX in killing tumor cells derived from patients with de novo or relapsed B-cell lymphoma. In addition, OFA was more effective in controlling in vivo lymphoma growth than RTX. The median survival for animals treated with OFA (1 or 10mg/kg/dose) [58 and 77 days] was longer than those treated with RTX [40 and 50 days]. While the activity of RTX diminished with CD20 down-regulation in RRCL passages, OFA activity was preserved even at low CD20 levels. Conclusions: Our data suggest that OFA is more potent than RTX not only in RTX-sensitive but also in RTX-resistant models. We are currently evaluating the biological effects of OFA in combination with a panel of chemotherapeutic agents and target-specific small molecule inhibitors. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Genmab, GlaxoSmithKline